Sean F Cooke, Thomas A Wright, Yuan Yan Sin, Jiayue Ling, Elka Kyurkchieva, Nattaporn Phanthaphol, Thomas Mcskimming, Katharine Herbert, Selma Rebus, Andrew V Biankin, David K Chang, George S Baillie, Connor M Blair
Pancreatic ductal adenocarcinoma (PDAC) is considered the third leading cause of cancer mortality in the western world, offering advanced stage patients with few viable treatment options. Consequently, there remains an urgent unmet need to develop novel therapeutic strategies that can effectively inhibit pro-oncogenic molecular targets underpinning PDACs pathogenesis and progression. One such target is c-RAF, a downstream effector of RAS that is considered essential for the oncogenic growth and survival of mutant RAS-driven cancers (including KRASMT PDAC)...
April 18, 2024: Scientific Reports